Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2022-05-19 00:00:00 ET · period of report 2022-05-17 · accession 0001567619-22-011300 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-19 | 2022-05-17 | PCSA | Lin Patrick | Chief Business - Strategy Off | P - Purchase | $1.59 | +2,000 | 433.4K | +0.5% | +$3,180 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-17 | P | A | 2,000 | $1.59 | 433,390 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.53 to $1.77, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. |